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Immunization -whether from polio, typhoid, lu or whoo-
ping cough- is never absolute. A shot in the arm may save 
your life -but you can’t always rely on it… Nor is any immu-
nization absolutely safe.1 
Inﬂuenza is a major cause of morbidity and mortality; cu-
rrent estimates by the World Health Organization (WHO) are 
3 to 5 million cases and 250,000 to 500,000 deaths worldwi-
de every year.2 Most deaths associated with it occur among 
people age 65 or older, as well as among persons suffering a 
chronic debilitating disease regardless of age. The recent 
2009 pandemic served to foster interest in this disease.3 
An inactivated virus vaccine has been available since the 
late 1940´s but it only began to be used extensively when 
the inﬂuenza virus antigenic variability was taken into ac-
count. Aside from such variability, inﬂuenza viruses are ca-
pable of infecting a wide variety of vertebrates,4 including 
many avian species, both wild and domestic, thus it is essen-
tial to monitor the antigenic characteristics of inﬂuenza virus 
strains currently circulating, and so the vaccine formula has 
to be evaluated and modiied accordingly every year.
Vaccine indications
The eficacy of inﬂuenza vaccine is relatively low (70%-90%)5 
and vaccinated persons could have insuficient protection 
even to homologous virus strains, not to mention those 
viruses that have undergone antigenic changes, either drift 
or shift. Furthermore, other respiratory viruses such as pa-
rainfluenza, adenoviruses or respiratory syncytial virus 
could cause a similar illness, frequent anecdotal comments 
of acute respiratory illness (ARI) coincident with vaccine 
application is therefore not too surprising.
The risk of complications during an inﬂuenza episode, lea-
ding to hospitalization and death is higher in older people 
(≥ 65 years) and in those patients undergoing any of a well-
known list of chronic debilitating diseases,6 yet the beneit 
of the inﬂuenza vaccine should be weighted in different si-
tuations. In Mexico, the Ministry of Health (Secretaría de 
Salud) recommends vaccine application to people belonging 
to certain groups7 (Table 1). 
Additional information to make better particular recom-
mendations for influenza vaccine use is available from 
WHO,8 as well as from the Advisory Committee on Immuni-
zation Practices9 in the United States of America:
• Healthy individuals: vaccination may be recom-
mended from age 50 onwards.
• Adults and children with health conditions such as 
chronic pulmonary disease (including asthma) or 
cardiovascular (except isolated hypertension), re-
nal, hepatic, neurological, hematologic, or meta-
bolic disorders (including diabetes mellitus).
• Persons who have immunosuppression, inclu-
ding compromised immune systems caused by 
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medications or human immunodeficiency virus 
(HIV) infection.
• Women who are or will be pregnant during the in-
ﬂuenza season.
• Children and adolescents (aged 6 months-18 years) 
who are receiving long-term aspirin therapy 
and who might be at risk for experiencing Reye’s 
syndrome after inﬂuenza virus infection.
• Residents of nursing homes and other long-term 
care facilities.
• Persons who are morbidly obese, with a body mass 
index (BMI) over 39.
Vaccine use and its public perception
Annual vaccination should take place ideally before the “ﬂu 
season” starts, that is, the months of September-October of 
each year; if uptake in this period is missed however, later 
vaccination is always encouraged, especially for persons at 
risk.
Although inﬂuenza vaccine is recommended by the WHO 
and is irmly established worldwide as an effective measure 
for inﬂuenza control, the number of persons who receive 
inﬂuenza vaccine each year is very low even in countries 
with good health systems.6,9 Fear of adverse effects has dis-
couraged public vaccine acceptance ever since Edward Jen-
ner irst proposed systematic smallpox prevention through 
cowpox immunization. The roots of this universal phenome-
non are myths and misinformation such as beliefs of vaccine 
being the cause of disease, lack of vaccine eficacy, refusal 
to get medical care, or plain mistrust of the health care 
system. A combination of these factors results in deicient 
vaccine coverage.
Data on factors inﬂuencing vaccine uptake, such as age, 
gender, co-morbidity, educational level, income and area of 
residence are important. However, recent research provides 
an insight on the reasons for vaccination acceptance or re-
jection; an improvement on vaccine acceptance requires a 
signiicant level of knowledge and understanding of health 
beliefs, attitudes, perceptions and subjective experiences 
both on individual and collective levels. This is particularly 
evident in older people, who decide to be vaccinated based 
on the interpretation and evaluation of beliefs about 
whether it could cause or prevent colds and inﬂuenza, and 
the importance of side effects. Older people’s subjective 
assessment of their own health is often incongruent with 
objective assessment.10
A group of police, ire ighters and prison workers in Spain, 
regarded as essential community workers, surveyed by Ca-
ballero et al.11 showed that the vaccine was better accepted 
by those who never had doubts about vaccine safety. 
In 2009, the Ministry of Health in France purchased 94 
million vaccine doses to ensure the vaccination of 65 million 
citizens. Yet, there was a low uptake of the vaccine that 
could have been related to a lack of high quality advice 
about the beneits of getting vaccinated; the same study 
also postulated that media and social networks may have 
contributed to raise undue concerns in the population. par-
ticipation of general practitioners may help to improve vac-
cine perception by providing face-to-face professional 
advice and information.12
Considerations for improvement
Many countries show vaccine uptake rates less than 50% in 
health care workers (HCW). livni et al. found the overall 
vaccination rate among a group of pediatric HCW in Israel 
was 46.8%. Their data show that knowledge about the 
inﬂuenza vaccine by health care personnel leads to better 
vaccination rates.13
Blasi et al. suggest improving communication between 
health authorities, scientiic societies, HCW and general po-
pulation through simple, clear, honest and straightforward 
messages to ensure unbiased information about the vaccine 
is the basis for a person to accept it.14
Septimus et al. established a mandatory vaccination pro-
gram for HCW aimed to foster patient safety, including cate-
gories for professional employees with patient care (clinical) 
duties as well as any other person who could be in the pre-
mises. The basis to establish these categories are: 1) access 
to clinical areas, and 2) work area within a 2 meter distance 
from the patient.15
Influenza vaccination rates are particularly low among 
marginalized, hard-to-reach urban populations, so interven-
tion activities are to be designed with a high degree of inter-
institutional cooperation, taking into account neighborhood 
particularities, strong community organization, and indivi-
dual orientation.16 
probabilistic models have the power to handle large 
amounts of data; these models are also suited to analyze 
Table 1 Groups considered a priority to get inﬂuenza vaccine, Ministry of Health (Secretaría de Salud), Mexico, 2014.
Contagion risk Individual risk Population characteristics  
High Low Health care personnel 
Low Low General (healthy) population
Low
High individual 
risk from 
medical 
complications
Age Children aged 6 months to 5 years, and people over 60
Debilitating conditions Any adult suffering obesity, diabetes, chronic lung disease, heart disease, HIV-infection or cancer
Pregnancy Women in any trimester of pregnancy
Adapted from Ministry of Health, Mexico.7  http://www.epidemiologia.salud.gob.mx/doctos/lineamientos/inﬂuenza/documento_
tecnico_inﬂuenza.pdf
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factors such as weather (low temperature, humidity, and 
rainfall), which has been widely anecdotically considered as 
associated with seasonal variation of ARI and inﬂuenza, and 
to enable better decision making, vaccination campaign 
planning and resource allocation during epidemics.17
American Indians and Alaskan natives are also groups tar-
geted for inﬂuenza vaccination in the United States of Ame-
rica, so we propose to study the benefits of preventing 
influenza in Mexican and other Meso-American ethnic 
groups. 
As we know from the past, fear and concern about vacci-
ne safety have been present from the beginning of vaccina-
tion during the 19th Century (Fig. 1). With an ever-increasing 
amount of internet and social network users, anti-vaccina-
tion messages lacking scientiic foundation may keep the 
public at large ill-informed and scared. HCW should 
be the best-informed group, with a solid knowledge of vac-
cination benefits and side effects. Vaccine perception 
should not be a black and white picture, but rather a balan-
ce between the many beneits obtained contrasted with a 
number of known and expected adverse effects. We have 
long postulated that a sound application of any vaccine has 
to be a carefully crafted beneit vs. risk evaluation, in other 
words, adverse reactions are to be considered the le- 
sser evil18 given the higher hospitalization and death rates 
among high-risk groups.
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Figure 1 Graphic depiction of fear elicited by smallpox vacci-
nation in 1802. painting by James Gillray (1756-1815). Image 
downloaded from the United States library of Congress’s prints 
and Photographs division under the digital ID cph.3g03147. 
This artistic work belongs in the public Domain according to 
World Trade Organization Agreement on Trade-Related Aspects 
of Intellectual property Rights (TRIpS), 1994.
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